Lisa Conte

  • Jaguar founder, president & CEO
  • Recognized pioneer in the investigation and development of plant-based prescription medicines for 30+ years
  • Editorial Advisory Board member of Life Science Leader magazine
  • Member of the Leadership Council of Pure Earth
  • M.S. in Physiology and Pharmacology from the University of California, San Diego; M.B.A. and A.B. in Biochemistry from Dartmouth College

Massimo Mineo

  • Chief Executive Officer

Joshua Mailman

  • NYC-based impact investor; co-founded Social Venture Network (now Social Venture Circle) in 1987
  • Founded Threshold Foundation in 1981; founded Business for Social Responsibility in 1992
  • Founded Serious Change L.P., a $100M privately held impact fund, in 2006
  • Founding investor in GonoPhone (Grameen Telecom) current market cap $4B
  • Founding investor in Global Telesystems with George Soros and Alan Slifka – grew to $5B market cap

Niccolò Caderni

  • Former European Space Agency Fellow at University of Cambridge
  • Former VP of M&A at Bankers Trust International; former chairman of Webiz
  • Former chiarman of RAFT, a leading research institute in field of regenerative medicine

Giovanni Maria Conti

  • Partner of Grimaldi Sudio Legale, a lawyers and chartered accountants’ professional firm in Italy
  • Extensive experience providing advisory services to national and international companies in the areas of corporate governance, finance transactions, M&A operations, and tax

John Micek III

  • Member of Jaguar’s board of directors
  • Board memeber and CEO/CFO of Enova Systems
  • Former managing director of Silicon Prairie Partners venture fund
  • Managing partner of Verdant Ventures, a merchant bank dedicated to sourcing and funding university and corporate lab spinouts in areas including pharmaceuticals and cleantech
  • Practicing California attorney specializing in financial services

Jonathan B. Siegel

  • Life sciences industry veteran with 21 + years experience investing and transacting in healthcare
  • CEO/Board Chairman of OPY Acquisition Corp. I, a publicly traded blank-check company that went public in 2021
  • CEO/Founder of JBS Healthcare Ventures, a firm he founded in 2017
  • Portfolio manager for healthcare with SAC Capital Advisors from 2005-2011

Massimo Radaelli

  • Pharmaceutical manager and entrepreneur with over 30 years of experience in the biopharmaceutical sector and innovation in therapies dedicated to rare diseases
  • He founded Noventia Pharma, Pint Pharma Group, Ferrer Italia and he is co-founder of Dupont-Merck JV Italian Subsidiary
  • He was president and CEO of Dompé International, as well as member of the boards of directors of Ariad Pharmaceuticals, Novabay, Philogen and IDRI
  • Today he is member of the boards of Pint Pharma Group, Bioakos Pharma Labs and Cytovia Threapeutics